🟠 Moderate Evidence
GLP-1 receptor agonists—the class of medications that includes semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda)—may reduce breast cancer risk by 17% among women with obesity or diabetes, according to research presented by Dr. Jennifer Martinez at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO). The findings, drawn from analysis of over 2.3 million patient records from the Optum Clinformatics database (2018-2024), represent the largest population study to examine cancer outcomes with these medications.
Key takeaways
- GLP-1 drugs reduced breast cancer incidence by 17% in a study of 2.3 million women with obesity or diabetes
- Cancer mortality decreased by 24% among breast cancer patients using these medications
- Benefits appeared strongest in postmenopausal women and those with BMI over 35
Study at a Glance
| Source | ASCO 2026 Annual Meeting |
| Study type | Retrospective cohort analysis |
| Sample size | N = 2.3 million |
| Population | Women with obesity or type 2 diabetes |
| Country | United States |
GLP-1 Drugs Show Protective Effect Against Breast Cancer
Risk reduction and mortality benefits, by patient subgroup
Source: ASCO 2026 Annual Meeting | Georgian Medical Journal News
Landmark Analysis Reveals Cancer Protection
The research, led by Dr. Jennifer Martinez at the Memorial Sloan Kettering Cancer Center, analyzed electronic health records from the Optum Clinformatics database spanning 2018 to 2024. Women prescribed GLP-1 receptor agonists showed a statistically significant 17% reduction in breast cancer incidence compared to those receiving standard diabetes or obesity treatments.
“This represents the most comprehensive real-world evidence to date suggesting these medications may have anti-cancer properties beyond their established metabolic benefits,” Dr. Martinez stated during her ASCO presentation. The study controlled for age, BMI, family history, and other cancer risk factors.
The protective effect appeared most pronounced among postmenopausal women (22% risk reduction) and those with severe obesity, defined as BMI greater than 35 kg/m² (21% risk reduction). For more related research developments, see our New Studies section.
Mortality Benefits Among Cancer Patients
Among the 18,472 women who developed breast cancer during the study period, those who had been using GLP-1 medications showed a 24% reduction in cancer-related mortality over a median follow-up of 3.2 years. This survival advantage persisted even after adjusting for cancer stage at diagnosis and treatment received.
Dr. Sarah Chen, an oncologist at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center who was not involved in the study, noted the findings align with emerging mechanistic research. “GLP-1 receptors are expressed in breast tissue, and these medications may influence tumor growth through insulin-sensitizing effects and direct cellular pathways,” she explained.
Mechanisms Behind Cancer Protection
GLP-1 receptor agonists work by mimicking the incretin hormone GLP-1, which regulates blood sugar and slows gastric emptying. Dr. Lisa Wong, an endocrinologist at the Mayo Clinic, noted that obesity itself is a known risk factor for breast cancer, particularly in postmenopausal women. “The cancer protection we’re seeing may result from both weight loss and independent molecular mechanisms,” she stated.
Our Clinical Updates section covers the latest treatment developments.
Clinical Implications and Future Research
The National Institutes of Health announced plans for a dedicated cancer prevention trial expected to begin enrollment in late 2026.
Dr. Martinez emphasized that the cancer benefits, while encouraging, should not be the primary reason for prescribing these medications. “These drugs should continue to be used for their proven indications—diabetes management and clinically significant weight loss in appropriate patients,” she stated.
Women using GLP-1 receptor agonists showed a 17% reduction in breast cancer incidence and 24% lower cancer mortality compared to standard care patients over 3.2 years of follow-up.
— Dr. Jennifer Martinez, Memorial Sloan Kettering Cancer Center (ASCO 2026)
What this means
Frequently asked questions
Should I start GLP-1 medications solely for cancer prevention?
No, these medications should only be prescribed for their established indications—type 2 diabetes management or clinically significant weight loss in patients with obesity. The cancer findings, while promising, require validation through randomized trials.
How long do patients need to use GLP-1 drugs to see cancer benefits?
The ASCO study showed protective effects emerging after approximately 18 months of treatment. However, optimal duration for cancer prevention has not been established, and individual patient factors vary significantly.
Are all GLP-1 medications equally protective against cancer?
The study included multiple GLP-1 receptor agonists including semaglutide, liraglutide, and dulaglutide, with similar protective effects observed across different medications in this drug class.
Source: Weight-Loss Drugs May Reduce Breast Cancer Risk and Mortality, New Studies Suggest
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
